BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
97.60
+7.62 (+8.47%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close89.98
Open90.43
Bid97.60 x 800
Ask99.90 x 1000
Day's Range90.00 - 98.80
52 Week Range75.81 - 100.03
Volume3,909,725
Avg. Volume1,354,742
Market Cap17.247B
Beta1.91
PE Ratio (TTM)N/A
EPS (TTM)-0.84
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est114.14
Trade prices are not sourced from all markets
  • BioMarin Begins Pediatric Study on Achondroplasia Candidate
    Zacks2 days ago

    BioMarin Begins Pediatric Study on Achondroplasia Candidate

    BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.

  • 3 Biotech Stocks Up in the Past Month on Industry Turnaround
    InvestorPlace3 days ago

    3 Biotech Stocks Up in the Past Month on Industry Turnaround

    After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.

  • PR Newswire4 days ago

    BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

    SAN RAFAEL, Calif., June 14, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that the company dosed the first participant in a global Phase 2 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in infants and young children with achondroplasia, the most common form of disproportionate short stature in humans. "Vosoritide represents an innovative therapy to treat the underlying cause of achondroplasia. At the molecular level, vosoritide corrects the signaling process that determines skeletal growth and proportionality of bones, while the body is still growing," said Hank Fuchs, M.D., President, Worldwide Research and Development at BioMarin.

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Why I Just Bought These 3 Stocks
    Motley Fool11 days ago

    Why I Just Bought These 3 Stocks

    There are thousands of publicly traded stocks, but I settled on adding these three to my portfolio this month.

  • PR Newswire11 days ago

    BioMarin Receives Milestone Payments from Pfizer for Talazoparib

    SAN RAFAEL, Calif. , June 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company received $20 million in milestone payments from Pfizer Inc.  These milestone ...

  • 3 Biotech Stocks Up in the Past Month on Industry Turnaround
    Zacks12 days ago

    3 Biotech Stocks Up in the Past Month on Industry Turnaround

    We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.

  • Why Sesen Bio Stock Jumped Over 37% this Week
    Market Realist16 days ago

    Why Sesen Bio Stock Jumped Over 37% this Week

    Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies based on Targeted Protein Therapeutics platform for the treatment of patients with cancer. The stock jumped ~26.1% to $2.27 yesterday. The above chart shows analysts’ recommendations for Sesen Bio over the last three months. The stock price has increased ~37.6% in last three trading sessions. It has increased by ~68.8% over the last 12 months and 201.8% year-to-date. On May 30, Sesen Bio announced the pricing of the underwritten public offering of ~22.2 million shares of its common stock at $1.80 per share, the closing price on May 30.

  • Catalyst's Fridapse Gets Priority Review by FDA, Shares Up
    Zacks17 days ago

    Catalyst's Fridapse Gets Priority Review by FDA, Shares Up

    The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.

  • 5 Biotech Stocks to Boost Your Portfolio’s Health This Year
    InvestorPlace17 days ago

    5 Biotech Stocks to Boost Your Portfolio’s Health This Year

    Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Drug pricing has been in the spotlight once again this month when President Donald Trump announced plans to lower prescription drug costs.

  • Analysts’ Recommendations for Incyte in May
    Market Realist18 days ago

    Analysts’ Recommendations for Incyte in May

    Wall Street analysts expect the company to see a 40.9% rise in revenue to $459.8 million in Q2 2018. Incyte’s stock price has fallen nearly 51.7% over the last 12 months and nearly 29.6% in 2018 year-to-date. Wall Street analysts’ recommendations show a 12-month target price of $81.0 per share compared to its price of $66.67 per share on May 24.

  • American City Business Journals18 days ago

    Why this biotech exec broke down on a conference call over company's new rare-disease drug

    Critics targeted the company's spending over 10 years of research and development on a drug that treats a rare, brain-damaging inherited disease. It was an emotional moment last week when the drug won approval.

  • TheStreet.com18 days ago

    Probing the Long Side of BioMarin

    In this updated daily bar chart of BMRN, below, we can see that the broader sideways trading range is still in place but in the past month BMRN has stayed above both the rising 50-day average line and the now rising 200-day line. The daily On-Balance-Volume (OBV) line has been steady this month and volume has recently increased. The trend-following Moving Average Convergence Divergence (MACD) oscillator dipped a little but is turning upwards again.

  • Allergan Recalls Taytulla Oral Contraceptives, Stock Down
    Zacks18 days ago

    Allergan Recalls Taytulla Oral Contraceptives, Stock Down

    Allergan (AGN) recalls some sample packs of Taytulla oral birth control pills. Shares decline.

  • Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod
    Zacks19 days ago

    Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod

    The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.

  • Here's Why Sarepta is Up More Than 60% So Far This Year
    Zacks19 days ago

    Here's Why Sarepta is Up More Than 60% So Far This Year

    Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.

  • ACCESSWIRE20 days ago

    Today’s Research Reports on Stocks to Watch: Ultragenyx Pharmaceutical and BioMarin Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / May 29, 2018 / Ultragenyx Pharma shares jumped after announcing its clinical trial results for Crysvita® ( burosumab), while BioMarin Pharma earned approval for its Palynziq™ ...

  • Which Is the Best Hemophilia Stock to Buy Now?
    Motley Fool23 days ago

    Which Is the Best Hemophilia Stock to Buy Now?

    New drugs to treat the rare bleeding disorder are on the way, but which drugmaker will come out ahead?

  • This Rare-Disease Biotech Scores an Important Win
    Motley Fool23 days ago

    This Rare-Disease Biotech Scores an Important Win

    The FDA has given a green light to a new drug that could generate hundreds of millions of dollars in annual revenue.

  • BioMarin's New Rare-Disease Med Costs 50% More Than Expected
    Investor's Business Daily23 days ago

    BioMarin's New Rare-Disease Med Costs 50% More Than Expected

    BioMarin Pharmaceutical spiked to a 16-week high Friday after it gained approval for a rare-disease drug and priced it about 50% higher than analysts expected.

  • BioMarin's Palynziq Gets FDA Approval for Phenylketonuria
    Zacks23 days ago

    BioMarin's Palynziq Gets FDA Approval for Phenylketonuria

    BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.

  • Benzinga24 days ago

    Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks Here are the biotech stocks that were hitting 52-week highs May 24:  ArQule, Inc. (NASDAQ: ARQL ) Baxter ...

  • A rare, brain-damaging disease faces a new foe: a $267K-a-year drug from a Bay Area stalwart
    American City Business Journals24 days ago

    A rare, brain-damaging disease faces a new foe: a $267K-a-year drug from a Bay Area stalwart

    This North Bay rare disease drug developer won its seventh regulatory approval, a potential replacement for one of its oldest (and most financially successful) drugs.

  • Stock Market Today: Track Market Trends And The Best Stocks To Watch
    Investor's Business Daily24 days ago

    Stock Market Today: Track Market Trends And The Best Stocks To Watch

    Check the Stock Market Today column to spot changes in market trend and track the best stocks to buy and watch.

  • Analyzing Ionis’s Q1 Revenue Streams
    Market Realist24 days ago

    Analyzing Ionis’s Q1 Revenue Streams

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) to $144.4 million from $145.3 million. Analysts expect its revenue to grow 30.2% YoY to $135.7 million in the second quarter. The graph below compares Ionis’s revenue since Q1 2017.